FM-VP4: Phase II started

FMI began a double-blind, placebo-controlled, U.S. Phase II trial in 150 hypercholesterolemic patients to evaluate the effect of 450 and 900 mg doses of FM-VP4 given for 12 weeks. FMI set a trial goal...